PTGX Announces Fast Track Designation by U.S. FDA Long

Protagonist Therapeutics, Inc.NASDAQ

Description

⋅ Sep 27, 2018 4:53 PM

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300